DocWire News Editors

DocwireNews

The use of beta-blockers in patients with heart failure, reduced ejection fraction, and renal dysfunction may be beneficial, according to new research published in the <a href="http://www.onlinejacc.org/content/74/23/2893">Journal of the American College of Cardiology</a>.&ldquo;Moderate and moderately severe renal impairment are common in patients with heart failure and reduced ejection fraction, but whether beta-blockers are effective is unclear, leading to under-use of life-saving therapy,&rdquo; study researchers for the Beta-Blockers in <a href="https://www.docwirenews.com/docwire-pick/cardiology-picks/heart-failure-virtual-visits-spironolactone/">Heart Failure</a> Collaborative Group explained. &ldquo;This study sought to investigate the patient prognosis and efficacy of beta-blockers according to renal function using estimated glomerular filtration rate (eGFR).&rdquo;The analysis included 16,740 individuals from 10 different double-blind, placebo-controlled studies, who all had left ventricular ejection fraction &lt;50%. The current analysis focused on all-cause mortality on an intention-to-treat basis. Baseline covariates were adjusted for and results were stratified by heart rhythm. Median follow-up was 1.3 years. Median eGFR at baseline was 63 mL/min/1.73 m2 (interquartile range: 50 to 77), with 4,584 patients (27.4%) having eGFR from 45 to 59 mL/min/1.73 m2, and 2,286 individuals(13.7%) having eGFR between 30 and 44 mL/min/1.73 m2.According to the results, eGFR was independently linked with mortality, a 12% increased risk for death for every 10 mL/min/1.73m2 reduction in eGFR (95% CI, 10% to 15%; P&lt;0.001). Beta-blockers were associated with reduced mortality versus placebo in 13,861 patients in sinus rhythm (adjusted HR=0.73 for eGFR range 45 to 59 mL/min/1.73 m2; 95% CI, 0.62 to 0.86; P&lt;0.001) and 0.71 for eGFR 30 to 44 mL/min/1.73 m2; 95% CI, 0.58 to 0.87; P&lt;0.001). No deterioration in renal function over time was reported in those patients with moderate or moderately severe renal impairment. There were also no reported differences in adverse events between those receiving beta-blockers and those taking placebo.&ldquo;Combining double-blind, individual patient-level data has provided a sufficient sample size to confirm the efficacy of beta-blockers in heart failure patients with reduced ejection fraction, sinus rhythm and renal dysfunction, including those with eGFR 30 to 44 mL/min/1.73 m2, the lowest range of eGFR tested in large placebo-controlled trials,&rdquo; the researchers wrote in their conclusion.<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
No benefit in atrial fibrillation, as seen globally in the The Beta-Blockers in Heart Failure Collaborative Group <a href="https://twitter.com/secardiologia?ref_src=twsrc%5Etfw">@secardiologia</a> <a href="https://twitter.com/SVCardio?ref_src=twsrc%5Etfw">@SVCardio</a> <a href="https://t.co/n1nIbVrykw">https://t.co/n1nIbVrykw</a>
&mdash; Enrique Santas (@SantasEnrique) <a href="https://twitter.com/SantasEnrique/status/1201591890329640960?ref_src=twsrc%5Etfw">December 2, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
&#128138;Beta-Blockers Do Not Disappoint!
Great article from Beta-Blockers in HF Collaborative Group and editorial&#128079;
B-blocker &#10549;&#65039; mortality in <a href="https://twitter.com/hashtag/HFrEF?src=hash&amp;ref_src=twsrc%5Etfw">#HFrEF</a> in sinus rhythm, including those with eGFR 45 to 59 and moderately severe (eGFR 30 to 44) renal dysfunction &#128206;<a href="https://t.co/aykrUMtVB4">https://t.co/aykrUMtVB4</a> <a href="https://t.co/0lFM1uuynA">pic.twitter.com/0lFM1uuynA</a>
&mdash; Nikolay Novitskiy (@novitskiynic) <a href="https://twitter.com/novitskiynic/status/1201758334711414785?ref_src=twsrc%5Etfw">December 3, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>https://twitter.com/MiguelCamafort/statuses/1201942751841071105&nbsp;

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

HER2 Breast Cancer

Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1+ mTNBC, Phase III Data Show

Triple-Negative Breast Cancer

Jordana Jampel

Actress Michelle Trachtenberg's Premature Death From Diabetes Reveals Dangers of Chronic Complications

Diabetes

Latest News

Beta-Blockers Recommended in HF Patients with Renal Dysfunction

Heart Failure

The use of beta-blockers in patients with heart failure, reduced ejection fraction, and renal dysfunction may be beneficial, according to new research published in the Journal ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe